News & Media

Press release Regulatory
Change in the number of shares and votes in Medivir AB (publ)

Stockholm – Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has...

Read more
Press release
Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 4 May 2023...

Read more
Press release Regulatory
Execution of the annual general meeting’s resolution on the removal of share class in Medivir AB (publ)

The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of...

Read more
Press release Regulatory
Resolutions at the Annual General Meeting in Medivir on 4 May 2023

Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2023

“Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase...

Read more
Press release
Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release Regulatory
Medivir 2022 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at the...

Read more
Press release Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release
Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Stockholm Corporate Finance Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more